
1. sci rep. 2017 aug 30;7(1):10062. doi: 10.1038/s41598-017-10672-9.

nanocurcumin superior native curcumin preventing degenerative changes in
experimental cerebral malaria.

dende c(1), meena j(2), nagarajan p(2), nagaraj va(3), panda ak(4), padmanaban
g(5).

author information: 
(1)department biochemistry, indian institute science, bengaluru, 560012,
india.
(2)national institute immunology, new delhi, 110067, india.
(3)infectious disease biology, institute life sciences, bhubaneswar, 751023,
india.
(4)national institute immunology, new delhi, 110067, india. amulya@nii.ac.in.
(5)department biochemistry, indian institute science, bengaluru, 560012,
india. geepee@biochem.iisc.ernet.in.

curcumin many pharmacological activities despite poor bioavailability and
in vivo stability. here, show nanoformulated curcumin (plga-curcumin)
has better therapeutic index native curcumin preventing onset of
neurological symptoms delaying death mice experimental cerebral
malaria. oral plga-curcumin least effective native curcumin a
15-fold lower concentration preventing breakdown blood-brain barrier
and inhibition brain mrnas inflammatory cytokines, chemokine receptor
cxcr3 ligand cxcl10, increase anti-inflammatory cytokine
il-10. also reflected serum cytokine chemokine levels. at
equivalent concentrations, single oral dose plga-curcumin effective
in inhibiting serum ifnγ levels enhancing il-10 levels native curcumin. 
even low concentrations, plga-curcumin superior native curcumin in
inhibiting sequestration parasitized-rbcs cd8+ cells brain. a
single oral dose 5 mg plga-curcumin containing 350 μg curcumin resulted 
3-4 fold higher concentration prolonged presence curcumin brain
than obtained 5 mg native curcumin, indicating better
bioavailability plga-curcumin. plga-curcumin potential adjunct drug 
to treat human cerebral malaria.

doi: 10.1038/s41598-017-10672-9 
pmcid: pmc5577147
pmid: 28855623  [indexed medline]

